Login to Your Account

Clinic Roundup

Friday, February 4, 2011
Inspiration Pharmaceuticals Inc., of Laguna Niguel, Calif., said results from the Phase I portion of an ongoing IB1001 study demonstrated noninferiority of the drug in achieving overall levels of replacement factor compared to BeneFIX, an approved recombinant FIX product for hemophilia B marketed by New York-based Pfizer Inc. Those data were presented at the European Association for Haemophilia and Allied Disorders meeting in Geneva.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription